Suberoylanilide hydroxamic acid (SAHA) has potent anti‐glioma properties in vitro, ex vivo and in vivo

Current treatment modalities for malignant gliomas do not allow long‐term survival. Here, we identify suberoylanilide hydroxamic acid (SAHA), an inhibitor of histone deacetylases (HDAC), as an effective experimental anti‐glioma agent. Administration of SAHA to various glioma cell lines obtained from human, rat and mouse inhibited tumour cell growth in a range of 1–10 μm. This anti‐glioma property is associated with up‐regulation of the cell cycle control protein p21/WAF, as well as the induction of apoptosis. A novel tumour invasion model using slice cultures of rat brain corroborated the anti‐glioma properties of SAHA in the organotypic brain environment. In this model, glioma invasion compromised adjacent brain parenchyma, and this tumour‐associated cytotoxicity could be inhibited by SAHA. In addition, a 10‐fold dose escalation experiment did not challenge the viability of cultured brain slices. In vivo, a single intratumoural injection of SAHA 7 days after orthotopic implantation of glioma cells in syngeneic rats doubled their survival time. These observations identify chromatin‐modifying enzymes as possible and promising targets for the pharmacotherapy of malignant gliomas.

[1]  Shin Jung,et al.  Brain tumor invasion model system using organotypic brain-slice culture as an alternative to in vivo model , 2002, Journal of Cancer Research and Clinical Oncology.

[2]  H. Namba,et al.  A histone deacetylase inhibitor enhances killing of undifferentiated thyroid carcinoma cells by p53 gene therapy. , 2002, The Journal of clinical endocrinology and metabolism.

[3]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[4]  T. Ekström,et al.  The human histone deacetylase family. , 2001, Experimental cell research.

[5]  T. Mikkelsen,et al.  Clonal expansion of p53 mutant cells is associated with brain tumour progression , 1992, Nature.

[6]  Y. Pommier,et al.  Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. , 2003, Cancer research.

[7]  T. Ohnishi,et al.  A novel model of glioma cell invasion using organotypic brain slice culture. , 1998, Cancer research.

[8]  L. Ko,et al.  Morphological characterization of nitrosourea-induced glioma cell lines and clones , 2004, Acta Neuropathologica.

[9]  I. Bechmann,et al.  Modification of microglia function protects from lesion‐induced neuronal alterations and promotes sprouting in the hippocampus , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[10]  L. Schwartz,et al.  Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  Y. Hofmann,et al.  Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. , 2003, Human molecular genetics.

[12]  G. Reifenberger,et al.  Expression of vimentin and glial fibrillary acidic protein in ethylnitrosourea-induced rat gliomas and glioma cell lines , 2004, Acta Neuropathologica.

[13]  D. Muller,et al.  A simple method for organotypic cultures of nervous tissue , 1991, Journal of Neuroscience Methods.

[14]  Anthony Asher,et al.  Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. , 2003, Journal of neurosurgery.

[15]  Jorge A. Almenara,et al.  The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. , 2003, Cancer research.

[16]  V. Richon,et al.  Histone deacetylase inhibitors as new cancer drugs , 2001, Current opinion in oncology.

[17]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[18]  S. Grant,et al.  The Histone Deacetylase Inhibitor MS-275 Promotes Differentiation or Apoptosis in Human Leukemia Cells through a Process Regulated by Generation of Reactive Oxygen Species and Induction of p 21 CIP 1 / WAF 1 1 , 2003 .

[19]  S. Inoue,et al.  Role of the histone deacetylase complex in acute promyelocytic leukaemia , 1998, Nature.

[20]  L. Ngo,et al.  Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[21]  L. D.,et al.  Brain tumors , 2005, Psychiatric Quarterly.

[22]  R. DePinho,et al.  Malignant glioma: genetics and biology of a grave matter. , 2001, Genes & development.

[23]  T. Golub,et al.  Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. , 2003, Cancer research.

[24]  A. Ruiz-García,et al.  Gcn5p is involved in the acetylation of histone H3 in nucleosomes , 1997, FEBS letters.

[25]  J. Dichgans,et al.  Anticonvulsant drugs fail to modulate chemotherapy-induced cytotoxicity and growth inhibition of human malignant glioma cells , 1998, Journal of Neuro-Oncology.

[26]  C. Van Lint,et al.  The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. , 1996, Gene expression.

[27]  D. Cohen,et al.  Histone Deacetylase Inhibition Selectively Alters the Activity and Expression of Cell Cycle Proteins Leading to Specific Chromatin Acetylation and Antiproliferative Effects* , 1999, The Journal of Biological Chemistry.

[28]  P. Marks,et al.  Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. , 2000, Journal of the National Cancer Institute.

[29]  D. Osoba,et al.  A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse , 2000, British Journal of Cancer.

[30]  A Krishan,et al.  Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining , 1975, The Journal of cell biology.

[31]  P. Marks,et al.  Histone deacetylases and cancer: causes and therapies , 2001, Nature Reviews Cancer.

[32]  A. V. van Kuilenburg,et al.  Histone deacetylases (HDACs): characterization of the classical HDAC family. , 2003, The Biochemical journal.

[33]  P. Marks,et al.  Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[34]  D. Bigner,et al.  Characterization of a spontaneous murine astrocytoma and abrogation of its tumorigenicity by cytokine secretion. , 1997, Neurosurgery.

[35]  C. Allis,et al.  Phosphorylation of histone H3 at serine 10 is correlated with chromosome condensation during mitosis and meiosis in Tetrahymena. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[36]  U. Weidle,et al.  Inhibition of histone deacetylases: a new strategy to target epigenetic modifications for anticancer treatment. , 2000, Anticancer research.

[37]  I. Blümcke,et al.  Malignant glioma-induced neuronal cell death in an organotypic glioma invasion model. Technical note. , 2005, Journal of neurosurgery.

[38]  J. Dichgans,et al.  One week on/one week off: A novel active regimen of temozolomide for recurrent glioblastoma , 2004, Neurology.

[39]  Michael Weller,et al.  Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo , 2002, Nature Medicine.

[40]  A. Verdel,et al.  Functional significance of histone deacetylase diversity. , 2001, Current opinion in genetics & development.

[41]  David N Louis,et al.  Oligodendroglioma: Toward Molecular Definitions in Diagnostic Neuro‐Oncology , 2003, Journal of neuropathology and experimental neurology.

[42]  Leslie M Thompson,et al.  Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease , 2003, Proceedings of the National Academy of Sciences of the United States of America.